ArticleInternational journal of pharmaceutics: X2026
Liquisolids as a platform for the formulation of cannabis tablets.
Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesoporous silica-based liquisolids offer an effective method for transforming liquid or sticky actives, such as cannabis extracts, into free-flowing powders. This approach broadens the formulation strategies available for these actives, which are typically limited to liquid formulations or soft gelatin encapsulation, by facilitating the formulation of tablets. However, tableting liquisolids is challenging due to issues including low tensile strength, capping and delamination. Overcoming these challenges requires careful selection of excipients and tableting parameters to produce tablets with sufficient tensile strength while also maintaining high Overall Liquid Load. In our study, we utilized a 65/35 volumetric ratio of 0.75 mL/g liquid loaded Syloid® XDP 3050 silica and Vivapur® 101 as a binder/filler to formulate cannabis liquisolid tablets with a target THC dose of 10 mg per tablet. Findings indicated that a 4% concentration of Kollidon® CL-F was optimal for disintegration, while 0.5% magnesium stearate proved to be the most effective lubricant concentration. Utilizing a rotary press compaction cycle on a StylOne® compaction simulator, we found precompression around half the main compaction pressure allowed for maximizing tableting speed while maintaining high tensile strength and keeping tablet defects to a minimum. The resulting cannabis liquisolid tablets demonstrated a tensile strength of 1.58 N/mm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.